Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy

Clinical Infectious Diseases

Volumn 56, Issue 6, 2013, Pages 880-887

  Chaix, Marie Laure ^a   Seng, Remonie ^b   Frange, Pierre ^a,c   Tran, Laurent ^b   Avettand Fenoël, Véronique ^a   Ghosn, Jade ^a,d   Reynes, Jacques ^e   Yazdanpanah, Yazdan ^f   Raffi, François ^g   Goujard, Cécile ^b,d   Rouzioux, Christine ^a   Meyer, Laurence ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d BICÊTRE HOSPITAL   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f BICHAT HOSPITAL   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

cART; HIV 1 primary infection; subtype

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FRANCE; GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MICROBIAL DIVERSITY; PHYLOGENETIC TREE; PRIMARY HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTASE GENE; VIROLOGY; VIRUS STRAIN;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CLUSTER ANALYSIS; FEMALE; FRANCE; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; PHYLOGENY; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84874779902     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis999     Document Type: Article

References (47)

1. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25:679-89.
2. Deroo S, Robert I, Fontaine E, et al. HIV-1 subtypes in Luxembourg, 1983-2000. AIDS 2002; 16:2461-7.
3. Boni J, Pyra H, Gebhardt M, et al. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J Acquir Immune Defic Syndr 1999; 22:174-9.
4. Lospitao E, Alvarez A, Soriano V, Holguin A. HIV-1 subtypes in Spain: a retrospective analysis from 1995 to 2003. HIV Med 2005; 6:313-20.
5. Machuca R, Bogh M, Salminen M, et al. HIV-1 subtypes in Denmark. Scand J Infect Dis 2001; 33:697-701.
6. Snoeck J, Van Laethem K, Hermans P, et al. Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001. J Acquir Immune Defic Syndr 2004; 35:279-85.
7. Sonnerborg A, Durdevic S, Giesecke J, Sallberg M. Dynamics of the HIV-1 subtype distribution in the Swedish HIV-1 epidemic during the period 1980 to 1993. AIDS Res Hum Retroviruses 1997; 13:343-5.
8. Chaix ML, Descamps D, Wirden M, et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009; 23:717-24.
9. Descamps D, Chaix ML, Montes B, et al. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother 2010; 65:2620-7.
10. Semaille C, Barin F, Cazein F, et al. Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France. J Infect Dis 2007; 196:377-83.
11. Brennan CA, Bodelle P, Coffey R, et al. HIV global surveillance: foundation for retroviral discovery and assay development. J Med Virol 2006; 78(suppl 1):S24-9.
12. Kiwanuka N, Laeyendecker O, Quinn TC, et al. HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. AIDS 2009; 23:2479-84.
13. Renjifo B, Gilbert P, Chaplin B, et al. Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS 2004; 18:1629-36.
14. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197:707-13.
15. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195:1177-80.
16. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843-52.
17. Katzenstein D. Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa. J Infect Dis 2006; 194(suppl 1):S45-50.
18. Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 2007; 81:10209-19.
19. Vergne L, Snoeck J, Aghokeng A, et al. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol Med Microbiol 2006; 46:53-62.
20. Vergne L, Stuyver L, Van Houtte M, Butel C, Delaporte E, Peeters M. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol 2006; 36:43-9.
21. Ghosn J, Delaugerre C, Flandre P, et al. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. PLoS One 2011; 6: e24798.
22. Bannister WP, Ruiz L, Loveday C, et al. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther 2006; 11:707-15.
23. Scherrer AU, Ledergerber B, von Wyl V, et al. Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis 2011; 53:1143-52.
24. Pillay D, Walker AS, Gibb DM, et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 2002; 186:617-25.
25. Bocket L, Cheret A, Deuffic-Burban S, et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 2005; 10:247-54.
26. Bouchaud O, Le Moing V, Simon F, et al. Similar short-term efficacy of antiretroviral therapy in patients infected with HIV B and non-B subtype strains in France. J Acquir Immune Defic Syndr 2011; 56:67-9.
27. Ghosn J, Deveau C, Chaix ML, et al. Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. J Antimicrob Chemother 2010; 65:741-8.
28. Pasquier C, Millot N, Njouom R, et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods 2001; 94:45-54.
29. Barin F, Plantier JC, Brand D, et al. Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic. J Med Virol 2006; 78(suppl 1):S13-8.
30. Aiyar A. The use of CLUSTAL W and CLUSTAL X for multiple sequence alignment. Methods Mol Biol 2000; 132:221-41.
31. Felsenstein J. An alternating least squares approach to inferring phylogenies from pairwise distances. Syst Biol 1997; 46:101-11.
32. Retief JD. Phylogenetic analysis using PHYLIP. Methods Mol Biol 2000; 132:243-58.
33. Vidal N, Frange P, Chaix ML, et al. Characterization of an old complex circulating recombinant form, CRF27-cpx, originating from the Democratic Republic of Congo (DRC) and circulating in France. AIDS Res Hum Retroviruses 2008; 24:315-21.
34. Frange P, Galimand J, Vidal N, et al. New and old complex recombinant HIV-1 strains among patients with primary infection in 1996- 2006 in France: the French ANRS CO06 PRIMO Cohort study. Retrovirology 2008; 5:69.
35. Galimand J, Frange P, Rouzioux C, et al. Short communication: evidence of HIV type 1 complex and second generation recombinant strains among patients infected in 1997-2007 in France: ANRS CO06 PRIMO Cohort. AIDS Res Hum Retroviruses 2010; 26:645-51.
36. Leoz M, Chaix ML, Delaugerre C, et al. Circulation of multiple patterns of unique recombinant forms B/CRF02-AG in France: precursor signs of the emergence of an upcoming CRF B/02. AIDS 2011; 25:1371-7.
37. Thomson MM, Najera R. Increasing HIV-1 genetic diversity in Europe. J Infect Dis 2007; 196:1120-4.
38. Paraskevis D, Pybus O, Magiorkinis G, et al. Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology 2009; 6:49.
39. Yerly S, von Wyl V, Ledergerber B, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007; 21:2223-9.
40. von Wyl V, Kouyos RD, Yerly S, et al. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. J Infect Dis 2011; 204:1095-1103.
41. Alexander CS, Montessori V, Wynhoven B, et al. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral- naive individuals in British Columbia. Antivir Ther 2002; 7:31-5.
42. Easterbrook PJ, Smith M, Mullen J, et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 2010; 13:4.
43. Geretti AM, Harrison L, Green H, et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009; 48:1296-1305.
44. Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16:1139-46.
45. Jensen-Fangel S, Pedersen L, Pedersen C, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002; 35:1541-8.
46. Giordano TP, Wright JA, Hasan MQ, White AC Jr., Graviss EA, Visnegarwala F. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis 2003; 37:433-7.
47. de Arellano ER, Benito JM, Soriano V, Lopez M, Holguin A. Impact of ethnicity and HIV type 1 subtype on response to first-line antiretroviral therapy. AIDS Res Hum Retroviruses 2007; 23:891-4.